This is data of early studies looking at how people handle daclizumab (an antibody that blocks T cell function and augments a subset of Natural killer cells. They found they could get the dose for a once a month dosing. The results of the phase III trial inMS was presented at ECTRIMS2014 and there was a significantly better effect than using beta interferon. The major side effect was skin reactions at the site of injections, which could be treated with steroids. So this is going to be the next new MS drug. We will report on this as the data is published